__NUXT_JSONP__("/drugs/Cytarabine", (function(a,b,c,d,e,f,g,h,i,j){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[{brand:a,indication:"INDICATIONS AND USAGE Cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of cytarabine injection (preservative-free only) is indicated for the prophylaxis and treatment of meningeal leukemia.",manufacturer:c,splSetId:"21e8e8e6-3f85-4fdd-8452-c9d14d2ef69a"},{brand:a,indication:b,manufacturer:c,splSetId:"277597b0-7d85-40a3-a34a-70c6a883fc6d"},{brand:a,indication:b,manufacturer:d,splSetId:"34803a0e-f54d-4147-8f9f-7d0e3a007756"},{brand:a,indication:b,manufacturer:e,splSetId:"446f6765-5375-6368-4755-4944574f5721"},{brand:f,indication:g,manufacturer:c,splSetId:"681b5dc4-4fcf-4fab-ad78-02cb9a4a5dd0"},{brand:a,indication:b,manufacturer:h,splSetId:"7ab50348-ca78-46a5-aba6-c35b6b21fbfe"},{brand:"VYXEOS",indication:"1 INDICATIONS AND USAGE VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. VYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor, that is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. ( 1 )",manufacturer:"Jazz Pharmaceuticals, Inc.",splSetId:"7ea701ce-e7d3-4349-a9c2-642a501d45c8"},{brand:a,indication:b,manufacturer:e,splSetId:"8105e590-fc7e-45b7-9604-c2d0d1be5eac"},{brand:a,indication:g,manufacturer:d,splSetId:"b48842dd-c5c9-484c-a3f5-cb883919b418"},{brand:a,indication:b,manufacturer:c,splSetId:"bc2fa221-ea56-48b8-8304-42cd81b8463b"},{brand:a,indication:"INDICATIONS AND USAGE: Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute non-lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia.",manufacturer:"Fresenius Kabi USA, LLC",splSetId:"c4fdc56e-efd7-4825-a518-ef430b2b3df0"},{brand:a,indication:b,manufacturer:h,splSetId:"cb0db038-4a65-42c7-aa79-5c88309061df"},{brand:i,indication:"INDICATIONS AND USAGE Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparation only) is indicated in the prophylaxis and treatment of meningeal leukemia.",manufacturer:d,splSetId:"ee6decae-7e1b-45cf-b2d0-c15946d8fa1f"}],id:a,nciThesaurus:{casRegistry:"147-94-4",chebiId:"CHEBI:28680",chemicalFormula:"C9H13N3O5",definition:"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair.",fdaUniiCode:"04079A1RDZ",identifier:"C408",preferredName:a,semanticType:"Nucleic Acid, Nucleoside, or Nucleotide",subclassOf:["C1557"],synonyms:[".beta.-Cytosine arabinoside","1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-.beta.-D-Arabinofuranosylcytosine","1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-Beta-D-arabinofuranosylcytosine","1.beta.-D-Arabinofuranosylcytosine","2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-","2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-","4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone","ARA-cell","Alexan","Ara-C","Arabine","Arabinofuranosylcytosine","Arabinosylcytosine","Aracytidine","Aracytin","Aracytine","Beta-Cytosine Arabinoside","Beta-cytosine Arabinoside","CHX-3311",f,a,"Cytarabinum","Cytarbel","Cytosar","Cytosar-U","Cytosine Arabinoside","Cytosine-.beta.-arabinoside","Cytosine-beta-arabinoside","Erpalfa","Starasid","Tarabine PFS","U 19920","U-19920","Udicil","WR-28453",i]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FCytarabine",extension:".json",createdAt:j,updatedAt:j}}],fetch:{},mutations:void 0}}("Cytarabine","INDICATIONS AND USAGE Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia.","Hospira, Inc.","Mylan Institutional LLC","Meitheal Pharmaceuticals Inc.","CYTARABINE","INDICATIONS AND USAGE Cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of cytarabine is indicated in the prophylaxis and treatment of meningeal leukemia.","Gland Pharma Limited","cytarabine","2021-10-30T13:39:47.383Z")));